Triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United
States from 2012 to 2016, with a 5-year survival 8% to 16% lower than hormone receptor …

Background Triple‐negative breast cancer (TNBC) has been associated with a more
aggressive histology, poorer prognosis, and nonresponsiveness to hormone therapy. It is …

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that
disproportionately affects BRCA1 mutation carriers and young women of African origin …

Background Although diagnosed less often, breast cancer in African American women
(AAW) displays different characteristics compared to breast cancer in Caucasian women …

Background Triple-negative breast cancer (TNBC) occurs at higher frequency in African
Americans compared with Caucasians. It is unclear if the biology of TNBC is different in …

Breast cancer is a major problem for global public health. Breast Cancer is the most
common incident form of cancer in women around the world. The incidence is increasing …

Triple-negative (ER-negative, PR-negative, HER2/neu not overexpressed) breast cancer
has distinct clinical and pathologic features, and is a clinical problem because of its …

Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for
expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is …

Of the estimated 1 million cases of breast cancer diagnosed annually worldwide, it is
estimated that over 170,000 will harbor the triple-negative (estrogen receptor/progesterone …

Triple-negative breast cancer has recently been recognized as an important subgroup of
breast cancer with a distinct outcome and therapeutic approach when compared with other …